Silence....that word seems to be found in many posts over the last few months. May I humbly remind my fellow investors that silence does not equate to inaction. There is a level of activity and preparation involved with the start of three trials which would be a challenge for a large established biotech much less our tiny company. I've made the comparison of Anavex and Biogen in manpower and functional capabilities before. So IMHO Anavex is working "all the moving parts" feverishly and competently as we grumble about PR's and share price. We will look back at this period and think it wasn't patience but the thrill of anticipation which kept us going.
Just a restate of a previous post on "all the moving parts' that Chris, Tom, the BOD and the SAB are dealing with as we sleep safely in our beds.
-----
Chris Missling is like an experienced Company Commander or 4 Ship Flight Lead in the the Military. They are focused on the mission and often don't have time to brief their troops on every move. The troops have to trust his experience and judgement and follow his command during the battle. Missling's focus is on the mission of getting 2-73 through drug development to approval. His attention at this point is on "all the moving parts" i.e. the FDA/CDER, RS Org, MJFF, AUSG/Alfred Health, and possibly Biogen. Then their could be other players like our institutional investors, BP/Bio's, and govt agencies like the NIH/NIA and even the Administration and Congress.
We are in the heat of battle. and the battle plan may be classified. He will have much to share with us when we regroup for a breather during a lull in the action.
